HIV drug resistance , Users Manual
December 2017
Guidelines
June 2017
HIV strategic information for impact
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... the effectiveness of medically important antimicrobials, particularly those antimicrobials judged to be critically important to human medicine and also help preserve the effectiveness of antimicrobials for veterinary medicine, in direct support of the WHO global action plan on antimicrobial resistance
more
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...d over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. The disease is endemic in 72 countries. In 2016, an estimated total population of 856 million were living in areas with ongoing transmission of the causative filarial parasites and requiring mass drug administration (MDA). Lymphatic filariasis disfigures and disables, and often leads to stigmatization and poverty. Hundreds of millions of dollars are lost annually due to reduced productivity of affected patients. WHO has ranked the disease as one of the world’s leading causes of permanent and long-term disability.
more
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
WHO clinical guidelines.
For the first time, WHO has published guidelines to help (primarily) front-line healthcare providers give high-quality, compassionate, and respectful care to children and adolescents (up to age 18) who have or may have experienced sexual abuse, including sexual assault or r...ape.
more